nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Estradiol—prostate cancer	0.119	0.231	CbGbCtD
Naltrexone—UGT1A1—Etoposide—prostate cancer	0.078	0.151	CbGbCtD
Naltrexone—ABCB1—Estramustine—prostate cancer	0.064	0.124	CbGbCtD
Naltrexone—ABCB1—Cabazitaxel—prostate cancer	0.0422	0.0816	CbGbCtD
Naltrexone—ABCB1—Estrone—prostate cancer	0.0413	0.0797	CbGbCtD
Naltrexone—ABCB1—Ethinyl Estradiol—prostate cancer	0.0368	0.071	CbGbCtD
Naltrexone—ABCB1—Conjugated Estrogens—prostate cancer	0.027	0.0521	CbGbCtD
Naltrexone—ABCB1—Mitoxantrone—prostate cancer	0.0245	0.0474	CbGbCtD
Naltrexone—ABCB1—Estradiol—prostate cancer	0.0237	0.0458	CbGbCtD
Naltrexone—ABCB1—Prednisone—prostate cancer	0.0204	0.0394	CbGbCtD
Naltrexone—ABCB1—Etoposide—prostate cancer	0.0155	0.0299	CbGbCtD
Naltrexone—ABCB1—Docetaxel—prostate cancer	0.0142	0.0274	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—prostate cancer	0.0106	0.0204	CbGbCtD
Naltrexone—UGT1A1—urine—prostate cancer	0.00712	0.353	CbGeAlD
Naltrexone—OPRK1—prostate gland—prostate cancer	0.00283	0.14	CbGeAlD
Naltrexone—UGT1A1—prostate gland—prostate cancer	0.00256	0.127	CbGeAlD
Naltrexone—OPRD1—renal system—prostate cancer	0.00201	0.0997	CbGeAlD
Naltrexone—UGT1A1—renal system—prostate cancer	0.00174	0.0864	CbGeAlD
Naltrexone—Morphine—UGT2B15—prostate cancer	0.00155	0.238	CrCbGaD
Naltrexone—Naloxone—TLR4—prostate cancer	0.00121	0.186	CrCbGaD
Naltrexone—OPRM1—testis—prostate cancer	0.000886	0.0439	CbGeAlD
Naltrexone—Buprenorphine—CYP2C18—prostate cancer	0.000611	0.0938	CrCbGaD
Naltrexone—ABCB1—prostate gland—prostate cancer	0.00058	0.0288	CbGeAlD
Naltrexone—ABCB1—seminal vesicle—prostate cancer	0.000491	0.0243	CbGeAlD
Naltrexone—Oxycodone—CYP3A5—prostate cancer	0.000437	0.0671	CrCbGaD
Naltrexone—ABCB1—epithelium—prostate cancer	0.000426	0.0211	CbGeAlD
Naltrexone—Buprenorphine—CYP3A5—prostate cancer	0.000403	0.0618	CrCbGaD
Naltrexone—ABCB1—renal system—prostate cancer	0.000395	0.0196	CbGeAlD
Naltrexone—Buprenorphine—CYP2A6—prostate cancer	0.00039	0.0598	CrCbGaD
Naltrexone—ABCB1—urethra—prostate cancer	0.000388	0.0193	CbGeAlD
Naltrexone—Naloxone—ESR1—prostate cancer	0.000339	0.052	CrCbGaD
Naltrexone—ABCB1—bone marrow—prostate cancer	0.000299	0.0148	CbGeAlD
Naltrexone—Buprenorphine—CYP2C19—prostate cancer	0.000274	0.0421	CrCbGaD
Naltrexone—ABCB1—testis—prostate cancer	0.000256	0.0127	CbGeAlD
Naltrexone—Oxymorphone—CYP3A4—prostate cancer	0.000237	0.0364	CrCbGaD
Naltrexone—Hydrocodone—CYP3A4—prostate cancer	0.000207	0.0318	CrCbGaD
Naltrexone—Oxycodone—CYP3A4—prostate cancer	0.000189	0.029	CrCbGaD
Naltrexone—ABCB1—lymph node—prostate cancer	0.000185	0.00918	CbGeAlD
Naltrexone—Buprenorphine—CYP3A4—prostate cancer	0.000174	0.0268	CrCbGaD
Naltrexone—Naloxone—CYP3A4—prostate cancer	0.000173	0.0266	CrCbGaD
Naltrexone—Hydromorphone—CYP3A4—prostate cancer	0.000172	0.0264	CrCbGaD
Naltrexone—Morphine—CYP3A4—prostate cancer	0.000146	0.0224	CrCbGaD
Naltrexone—Tachycardia—Capecitabine—prostate cancer	6.15e-05	0.000184	CcSEcCtD
Naltrexone—Pharyngitis—Epirubicin—prostate cancer	6.13e-05	0.000184	CcSEcCtD
Naltrexone—Skin disorder—Capecitabine—prostate cancer	6.12e-05	0.000183	CcSEcCtD
Naltrexone—Hyperhidrosis—Capecitabine—prostate cancer	6.09e-05	0.000182	CcSEcCtD
Naltrexone—Connective tissue disorder—Epirubicin—prostate cancer	6.07e-05	0.000182	CcSEcCtD
Naltrexone—Loss of consciousness—Prednisone—prostate cancer	6.04e-05	0.000181	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—prostate cancer	6.02e-05	0.00018	CcSEcCtD
Naltrexone—Epistaxis—Doxorubicin—prostate cancer	6e-05	0.00018	CcSEcCtD
Naltrexone—Anorexia—Capecitabine—prostate cancer	6e-05	0.00018	CcSEcCtD
Naltrexone—Nausea—Estradiol—prostate cancer	6e-05	0.00018	CcSEcCtD
Naltrexone—Vomiting—Mitoxantrone—prostate cancer	5.98e-05	0.000179	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—prostate cancer	5.97e-05	0.000179	CcSEcCtD
Naltrexone—Convulsion—Prednisone—prostate cancer	5.96e-05	0.000178	CcSEcCtD
Naltrexone—Hypertension—Prednisone—prostate cancer	5.93e-05	0.000178	CcSEcCtD
Naltrexone—Rash—Mitoxantrone—prostate cancer	5.93e-05	0.000178	CcSEcCtD
Naltrexone—Dermatitis—Mitoxantrone—prostate cancer	5.93e-05	0.000178	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Docetaxel—prostate cancer	5.93e-05	0.000178	CcSEcCtD
Naltrexone—Headache—Mitoxantrone—prostate cancer	5.89e-05	0.000177	CcSEcCtD
Naltrexone—Insomnia—Docetaxel—prostate cancer	5.88e-05	0.000176	CcSEcCtD
Naltrexone—Myalgia—Prednisone—prostate cancer	5.85e-05	0.000175	CcSEcCtD
Naltrexone—Arthralgia—Prednisone—prostate cancer	5.85e-05	0.000175	CcSEcCtD
Naltrexone—Paraesthesia—Docetaxel—prostate cancer	5.84e-05	0.000175	CcSEcCtD
Naltrexone—Anxiety—Prednisone—prostate cancer	5.83e-05	0.000175	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.81e-05	0.000174	CcSEcCtD
Naltrexone—Dyspnoea—Docetaxel—prostate cancer	5.8e-05	0.000174	CcSEcCtD
Naltrexone—Somnolence—Docetaxel—prostate cancer	5.78e-05	0.000173	CcSEcCtD
Naltrexone—Discomfort—Prednisone—prostate cancer	5.78e-05	0.000173	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—prostate cancer	5.77e-05	0.000173	CcSEcCtD
Naltrexone—Hypersensitivity—Etoposide—prostate cancer	5.77e-05	0.000173	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—prostate cancer	5.76e-05	0.000172	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.74e-05	0.000172	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—prostate cancer	5.73e-05	0.000172	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—prostate cancer	5.71e-05	0.000171	CcSEcCtD
Naltrexone—Insomnia—Capecitabine—prostate cancer	5.7e-05	0.000171	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—prostate cancer	5.67e-05	0.00017	CcSEcCtD
Naltrexone—Paraesthesia—Capecitabine—prostate cancer	5.65e-05	0.000169	CcSEcCtD
Naltrexone—Decreased appetite—Docetaxel—prostate cancer	5.65e-05	0.000169	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Docetaxel—prostate cancer	5.62e-05	0.000168	CcSEcCtD
Naltrexone—Asthenia—Etoposide—prostate cancer	5.62e-05	0.000168	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—prostate cancer	5.61e-05	0.000168	CcSEcCtD
Naltrexone—Dyspnoea—Capecitabine—prostate cancer	5.61e-05	0.000168	CcSEcCtD
Naltrexone—Anaphylactic shock—Prednisone—prostate cancer	5.61e-05	0.000168	CcSEcCtD
Naltrexone—Oedema—Prednisone—prostate cancer	5.61e-05	0.000168	CcSEcCtD
Naltrexone—Fatigue—Docetaxel—prostate cancer	5.61e-05	0.000168	CcSEcCtD
Naltrexone—Angiopathy—Epirubicin—prostate cancer	5.6e-05	0.000168	CcSEcCtD
Naltrexone—Nausea—Mitoxantrone—prostate cancer	5.59e-05	0.000167	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—prostate cancer	5.58e-05	0.000167	CcSEcCtD
Naltrexone—Infection—Prednisone—prostate cancer	5.57e-05	0.000167	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—prostate cancer	5.57e-05	0.000167	CcSEcCtD
Naltrexone—Constipation—Docetaxel—prostate cancer	5.56e-05	0.000167	CcSEcCtD
Naltrexone—Pain—Docetaxel—prostate cancer	5.56e-05	0.000167	CcSEcCtD
Naltrexone—Chills—Epirubicin—prostate cancer	5.54e-05	0.000166	CcSEcCtD
Naltrexone—Pruritus—Etoposide—prostate cancer	5.54e-05	0.000166	CcSEcCtD
Naltrexone—Shock—Prednisone—prostate cancer	5.52e-05	0.000165	CcSEcCtD
Naltrexone—Nervous system disorder—Prednisone—prostate cancer	5.5e-05	0.000165	CcSEcCtD
Naltrexone—Tachycardia—Prednisone—prostate cancer	5.47e-05	0.000164	CcSEcCtD
Naltrexone—Decreased appetite—Capecitabine—prostate cancer	5.47e-05	0.000164	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—prostate cancer	5.46e-05	0.000163	CcSEcCtD
Naltrexone—Skin disorder—Prednisone—prostate cancer	5.45e-05	0.000163	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Capecitabine—prostate cancer	5.44e-05	0.000163	CcSEcCtD
Naltrexone—Fatigue—Capecitabine—prostate cancer	5.43e-05	0.000163	CcSEcCtD
Naltrexone—Hyperhidrosis—Prednisone—prostate cancer	5.42e-05	0.000162	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—prostate cancer	5.41e-05	0.000162	CcSEcCtD
Naltrexone—Pain—Capecitabine—prostate cancer	5.39e-05	0.000161	CcSEcCtD
Naltrexone—Constipation—Capecitabine—prostate cancer	5.39e-05	0.000161	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—prostate cancer	5.38e-05	0.000161	CcSEcCtD
Naltrexone—Feeling abnormal—Docetaxel—prostate cancer	5.36e-05	0.000161	CcSEcCtD
Naltrexone—Diarrhoea—Etoposide—prostate cancer	5.36e-05	0.00016	CcSEcCtD
Naltrexone—Anorexia—Prednisone—prostate cancer	5.35e-05	0.00016	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—prostate cancer	5.34e-05	0.00016	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—prostate cancer	5.33e-05	0.00016	CcSEcCtD
Naltrexone—Gastrointestinal pain—Docetaxel—prostate cancer	5.32e-05	0.000159	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—prostate cancer	5.3e-05	0.000159	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—prostate cancer	5.3e-05	0.000159	CcSEcCtD
Naltrexone—Tension—Epirubicin—prostate cancer	5.28e-05	0.000158	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—prostate cancer	5.26e-05	0.000158	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—prostate cancer	5.22e-05	0.000156	CcSEcCtD
Naltrexone—Back pain—Epirubicin—prostate cancer	5.2e-05	0.000156	CcSEcCtD
Naltrexone—Feeling abnormal—Capecitabine—prostate cancer	5.19e-05	0.000155	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—prostate cancer	5.18e-05	0.000155	CcSEcCtD
Naltrexone—Dizziness—Etoposide—prostate cancer	5.18e-05	0.000155	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—prostate cancer	5.17e-05	0.000155	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—prostate cancer	5.16e-05	0.000155	CcSEcCtD
Naltrexone—Gastrointestinal pain—Capecitabine—prostate cancer	5.15e-05	0.000154	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—prostate cancer	5.15e-05	0.000154	CcSEcCtD
Naltrexone—Body temperature increased—Docetaxel—prostate cancer	5.14e-05	0.000154	CcSEcCtD
Naltrexone—Abdominal pain—Docetaxel—prostate cancer	5.14e-05	0.000154	CcSEcCtD
Naltrexone—Chills—Doxorubicin—prostate cancer	5.13e-05	0.000154	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Prednisone—prostate cancer	5.11e-05	0.000153	CcSEcCtD
Naltrexone—Insomnia—Prednisone—prostate cancer	5.07e-05	0.000152	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—prostate cancer	5.07e-05	0.000152	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—prostate cancer	5.05e-05	0.000151	CcSEcCtD
Naltrexone—Paraesthesia—Prednisone—prostate cancer	5.04e-05	0.000151	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—prostate cancer	5.01e-05	0.00015	CcSEcCtD
Naltrexone—Urticaria—Capecitabine—prostate cancer	5e-05	0.00015	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—prostate cancer	4.99e-05	0.000149	CcSEcCtD
Naltrexone—Body temperature increased—Capecitabine—prostate cancer	4.98e-05	0.000149	CcSEcCtD
Naltrexone—Abdominal pain—Capecitabine—prostate cancer	4.98e-05	0.000149	CcSEcCtD
Naltrexone—Vomiting—Etoposide—prostate cancer	4.98e-05	0.000149	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—prostate cancer	4.97e-05	0.000149	CcSEcCtD
Naltrexone—Agitation—Epirubicin—prostate cancer	4.94e-05	0.000148	CcSEcCtD
Naltrexone—Rash—Etoposide—prostate cancer	4.93e-05	0.000148	CcSEcCtD
Naltrexone—Dermatitis—Etoposide—prostate cancer	4.93e-05	0.000148	CcSEcCtD
Naltrexone—Headache—Etoposide—prostate cancer	4.9e-05	0.000147	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—prostate cancer	4.9e-05	0.000147	CcSEcCtD
Naltrexone—Tension—Doxorubicin—prostate cancer	4.88e-05	0.000146	CcSEcCtD
Naltrexone—Decreased appetite—Prednisone—prostate cancer	4.88e-05	0.000146	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—prostate cancer	4.87e-05	0.000146	CcSEcCtD
Naltrexone—Malaise—Epirubicin—prostate cancer	4.85e-05	0.000145	CcSEcCtD
Naltrexone—Fatigue—Prednisone—prostate cancer	4.84e-05	0.000145	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—prostate cancer	4.83e-05	0.000145	CcSEcCtD
Naltrexone—Syncope—Epirubicin—prostate cancer	4.82e-05	0.000144	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—prostate cancer	4.81e-05	0.000144	CcSEcCtD
Naltrexone—Constipation—Prednisone—prostate cancer	4.8e-05	0.000144	CcSEcCtD
Naltrexone—Hypersensitivity—Docetaxel—prostate cancer	4.79e-05	0.000144	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—prostate cancer	4.78e-05	0.000143	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—prostate cancer	4.75e-05	0.000142	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—prostate cancer	4.72e-05	0.000142	CcSEcCtD
Naltrexone—Cough—Epirubicin—prostate cancer	4.69e-05	0.000141	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—prostate cancer	4.69e-05	0.00014	CcSEcCtD
Naltrexone—Asthenia—Docetaxel—prostate cancer	4.67e-05	0.00014	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—prostate cancer	4.66e-05	0.00014	CcSEcCtD
Naltrexone—Nausea—Etoposide—prostate cancer	4.65e-05	0.000139	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—prostate cancer	4.64e-05	0.000139	CcSEcCtD
Naltrexone—Hypersensitivity—Capecitabine—prostate cancer	4.64e-05	0.000139	CcSEcCtD
Naltrexone—Feeling abnormal—Prednisone—prostate cancer	4.62e-05	0.000138	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—prostate cancer	4.61e-05	0.000138	CcSEcCtD
Naltrexone—Pruritus—Docetaxel—prostate cancer	4.6e-05	0.000138	CcSEcCtD
Naltrexone—Gastrointestinal pain—Prednisone—prostate cancer	4.59e-05	0.000137	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—prostate cancer	4.58e-05	0.000137	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—prostate cancer	4.58e-05	0.000137	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—prostate cancer	4.58e-05	0.000137	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—prostate cancer	4.57e-05	0.000137	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—prostate cancer	4.56e-05	0.000137	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	4.54e-05	0.000136	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—prostate cancer	4.52e-05	0.000135	CcSEcCtD
Naltrexone—Asthenia—Capecitabine—prostate cancer	4.52e-05	0.000135	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—prostate cancer	4.49e-05	0.000134	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—prostate cancer	4.48e-05	0.000134	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—prostate cancer	4.46e-05	0.000134	CcSEcCtD
Naltrexone—Urticaria—Prednisone—prostate cancer	4.46e-05	0.000134	CcSEcCtD
Naltrexone—Pruritus—Capecitabine—prostate cancer	4.46e-05	0.000133	CcSEcCtD
Naltrexone—Diarrhoea—Docetaxel—prostate cancer	4.45e-05	0.000133	CcSEcCtD
Naltrexone—Abdominal pain—Prednisone—prostate cancer	4.43e-05	0.000133	CcSEcCtD
Naltrexone—Body temperature increased—Prednisone—prostate cancer	4.43e-05	0.000133	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—prostate cancer	4.42e-05	0.000133	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—prostate cancer	4.4e-05	0.000132	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—prostate cancer	4.39e-05	0.000131	CcSEcCtD
Naltrexone—Oedema—Epirubicin—prostate cancer	4.39e-05	0.000131	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—prostate cancer	4.37e-05	0.000131	CcSEcCtD
Naltrexone—Infection—Epirubicin—prostate cancer	4.36e-05	0.000131	CcSEcCtD
Naltrexone—Cough—Doxorubicin—prostate cancer	4.34e-05	0.00013	CcSEcCtD
Naltrexone—Shock—Epirubicin—prostate cancer	4.32e-05	0.000129	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—prostate cancer	4.31e-05	0.000129	CcSEcCtD
Naltrexone—Diarrhoea—Capecitabine—prostate cancer	4.31e-05	0.000129	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—prostate cancer	4.3e-05	0.000129	CcSEcCtD
Naltrexone—Dizziness—Docetaxel—prostate cancer	4.3e-05	0.000129	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—prostate cancer	4.29e-05	0.000129	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—prostate cancer	4.28e-05	0.000128	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—prostate cancer	4.26e-05	0.000128	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—prostate cancer	4.24e-05	0.000127	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—prostate cancer	4.23e-05	0.000127	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—prostate cancer	4.23e-05	0.000127	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—prostate cancer	4.23e-05	0.000127	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—prostate cancer	4.22e-05	0.000126	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	4.21e-05	0.000126	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—prostate cancer	4.18e-05	0.000125	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—prostate cancer	4.18e-05	0.000125	CcSEcCtD
Naltrexone—Dizziness—Capecitabine—prostate cancer	4.16e-05	0.000125	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—prostate cancer	4.14e-05	0.000124	CcSEcCtD
Naltrexone—Vomiting—Docetaxel—prostate cancer	4.14e-05	0.000124	CcSEcCtD
Naltrexone—Hypersensitivity—Prednisone—prostate cancer	4.13e-05	0.000124	CcSEcCtD
Naltrexone—Rash—Docetaxel—prostate cancer	4.1e-05	0.000123	CcSEcCtD
Naltrexone—Dermatitis—Docetaxel—prostate cancer	4.1e-05	0.000123	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—prostate cancer	4.09e-05	0.000123	CcSEcCtD
Naltrexone—Headache—Docetaxel—prostate cancer	4.07e-05	0.000122	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—prostate cancer	4.06e-05	0.000122	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—prostate cancer	4.06e-05	0.000122	CcSEcCtD
Naltrexone—Infection—Doxorubicin—prostate cancer	4.03e-05	0.000121	CcSEcCtD
Naltrexone—Asthenia—Prednisone—prostate cancer	4.02e-05	0.000121	CcSEcCtD
Naltrexone—Vomiting—Capecitabine—prostate cancer	4e-05	0.00012	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—prostate cancer	4e-05	0.00012	CcSEcCtD
Naltrexone—Shock—Doxorubicin—prostate cancer	3.99e-05	0.00012	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—prostate cancer	3.98e-05	0.000119	CcSEcCtD
Naltrexone—Rash—Capecitabine—prostate cancer	3.97e-05	0.000119	CcSEcCtD
Naltrexone—Pruritus—Prednisone—prostate cancer	3.97e-05	0.000119	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—prostate cancer	3.97e-05	0.000119	CcSEcCtD
Naltrexone—Dermatitis—Capecitabine—prostate cancer	3.97e-05	0.000119	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—prostate cancer	3.96e-05	0.000119	CcSEcCtD
Naltrexone—Headache—Capecitabine—prostate cancer	3.95e-05	0.000118	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—prostate cancer	3.94e-05	0.000118	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—prostate cancer	3.94e-05	0.000118	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—prostate cancer	3.92e-05	0.000118	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—prostate cancer	3.91e-05	0.000117	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—prostate cancer	3.9e-05	0.000117	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—prostate cancer	3.87e-05	0.000116	CcSEcCtD
Naltrexone—Nausea—Docetaxel—prostate cancer	3.86e-05	0.000116	CcSEcCtD
Naltrexone—Diarrhoea—Prednisone—prostate cancer	3.84e-05	0.000115	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—prostate cancer	3.81e-05	0.000114	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—prostate cancer	3.79e-05	0.000113	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—prostate cancer	3.78e-05	0.000113	CcSEcCtD
Naltrexone—Constipation—Epirubicin—prostate cancer	3.75e-05	0.000112	CcSEcCtD
Naltrexone—Pain—Epirubicin—prostate cancer	3.75e-05	0.000112	CcSEcCtD
Naltrexone—Nausea—Capecitabine—prostate cancer	3.74e-05	0.000112	CcSEcCtD
Naltrexone—Dizziness—Prednisone—prostate cancer	3.71e-05	0.000111	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.7e-05	0.000111	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—prostate cancer	3.67e-05	0.00011	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—prostate cancer	3.65e-05	0.000109	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—prostate cancer	3.62e-05	0.000108	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—prostate cancer	3.62e-05	0.000108	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—prostate cancer	3.61e-05	0.000108	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—prostate cancer	3.59e-05	0.000107	CcSEcCtD
Naltrexone—Vomiting—Prednisone—prostate cancer	3.57e-05	0.000107	CcSEcCtD
Naltrexone—Rash—Prednisone—prostate cancer	3.54e-05	0.000106	CcSEcCtD
Naltrexone—Dermatitis—Prednisone—prostate cancer	3.53e-05	0.000106	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—prostate cancer	3.53e-05	0.000106	CcSEcCtD
Naltrexone—Headache—Prednisone—prostate cancer	3.51e-05	0.000105	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.5e-05	0.000105	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—prostate cancer	3.5e-05	0.000105	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—prostate cancer	3.49e-05	0.000104	CcSEcCtD
Naltrexone—Pain—Doxorubicin—prostate cancer	3.47e-05	0.000104	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—prostate cancer	3.47e-05	0.000104	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—prostate cancer	3.47e-05	0.000104	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—prostate cancer	3.47e-05	0.000104	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—prostate cancer	3.35e-05	0.0001	CcSEcCtD
Naltrexone—Nausea—Prednisone—prostate cancer	3.33e-05	9.98e-05	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—prostate cancer	3.32e-05	9.94e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—prostate cancer	3.23e-05	9.68e-05	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—prostate cancer	3.22e-05	9.66e-05	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—prostate cancer	3.21e-05	9.61e-05	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—prostate cancer	3.21e-05	9.61e-05	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—prostate cancer	3.15e-05	9.43e-05	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—prostate cancer	3.1e-05	9.3e-05	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—prostate cancer	3e-05	8.99e-05	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—prostate cancer	2.99e-05	8.96e-05	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—prostate cancer	2.91e-05	8.73e-05	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—prostate cancer	2.9e-05	8.69e-05	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—prostate cancer	2.87e-05	8.6e-05	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—prostate cancer	2.79e-05	8.36e-05	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—prostate cancer	2.78e-05	8.32e-05	CcSEcCtD
Naltrexone—Rash—Epirubicin—prostate cancer	2.77e-05	8.29e-05	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—prostate cancer	2.76e-05	8.28e-05	CcSEcCtD
Naltrexone—Headache—Epirubicin—prostate cancer	2.75e-05	8.23e-05	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—prostate cancer	2.68e-05	8.04e-05	CcSEcCtD
Naltrexone—Nausea—Epirubicin—prostate cancer	2.61e-05	7.81e-05	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—prostate cancer	2.58e-05	7.73e-05	CcSEcCtD
Naltrexone—Rash—Doxorubicin—prostate cancer	2.56e-05	7.67e-05	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—prostate cancer	2.56e-05	7.66e-05	CcSEcCtD
Naltrexone—Headache—Doxorubicin—prostate cancer	2.54e-05	7.62e-05	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—prostate cancer	2.41e-05	7.22e-05	CcSEcCtD
Naltrexone—ABCB1—Metabolism—GSTO1—prostate cancer	1.44e-05	0.000118	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NAT2—prostate cancer	1.44e-05	0.000118	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ADRB2—prostate cancer	1.44e-05	0.000118	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ITGB3—prostate cancer	1.43e-05	0.000117	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—JAK2—prostate cancer	1.42e-05	0.000116	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—MAP2K1—prostate cancer	1.41e-05	0.000116	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—LEP—prostate cancer	1.41e-05	0.000116	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CD—prostate cancer	1.4e-05	0.000115	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VAV3—prostate cancer	1.4e-05	0.000115	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CAV1—prostate cancer	1.4e-05	0.000115	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—CXCL8—prostate cancer	1.39e-05	0.000114	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PLCB2—prostate cancer	1.38e-05	0.000114	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LRP2—prostate cancer	1.38e-05	0.000114	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2C18—prostate cancer	1.38e-05	0.000114	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFBR2—prostate cancer	1.38e-05	0.000113	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB3—prostate cancer	1.38e-05	0.000113	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KDR—prostate cancer	1.38e-05	0.000113	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGFR2—prostate cancer	1.38e-05	0.000113	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—MTHFR—prostate cancer	1.37e-05	0.000113	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ITPR1—prostate cancer	1.36e-05	0.000112	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—P4HB—prostate cancer	1.36e-05	0.000111	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CB—prostate cancer	1.35e-05	0.000111	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PPARA—prostate cancer	1.35e-05	0.000111	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ESR1—prostate cancer	1.35e-05	0.000111	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL2—prostate cancer	1.33e-05	0.000109	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	1.33e-05	0.000109	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TERT—prostate cancer	1.33e-05	0.000109	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC22A1—prostate cancer	1.32e-05	0.000108	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—PPARA—prostate cancer	1.32e-05	0.000108	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—BAD—prostate cancer	1.32e-05	0.000108	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1R—prostate cancer	1.3e-05	0.000107	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—CXCL8—prostate cancer	1.3e-05	0.000106	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—JAK2—prostate cancer	1.29e-05	0.000106	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SULT2A1—prostate cancer	1.29e-05	0.000106	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	1.29e-05	0.000106	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—APC—prostate cancer	1.27e-05	0.000104	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CG—prostate cancer	1.27e-05	0.000104	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—HIF1A—prostate cancer	1.27e-05	0.000104	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CAV1—prostate cancer	1.27e-05	0.000104	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MED12—prostate cancer	1.27e-05	0.000104	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGF—prostate cancer	1.26e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IRS1—prostate cancer	1.26e-05	0.000103	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GNG5—prostate cancer	1.26e-05	0.000103	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LPL—prostate cancer	1.25e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—IL2—prostate cancer	1.24e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—LEP—prostate cancer	1.24e-05	0.000102	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PDGFRB—prostate cancer	1.24e-05	0.000101	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CAV1—prostate cancer	1.23e-05	0.000101	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CB—prostate cancer	1.22e-05	0.0001	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—GSK3B—prostate cancer	1.22e-05	0.0001	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KDR—prostate cancer	1.21e-05	9.95e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOA3—prostate cancer	1.21e-05	9.93e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—INS—prostate cancer	1.21e-05	9.89e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ITGB3—prostate cancer	1.21e-05	9.89e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ESR1—prostate cancer	1.18e-05	9.69e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CREBBP—prostate cancer	1.18e-05	9.69e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—CXCL8—prostate cancer	1.18e-05	9.65e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB3—prostate cancer	1.17e-05	9.59e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGFR2—prostate cancer	1.17e-05	9.57e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IGF1—prostate cancer	1.17e-05	9.57e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—EGFR—prostate cancer	1.16e-05	9.52e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CG—prostate cancer	1.15e-05	9.47e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—HPGDS—prostate cancer	1.15e-05	9.47e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—BAD—prostate cancer	1.15e-05	9.46e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2C19—prostate cancer	1.15e-05	9.41e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MAP2K1—prostate cancer	1.13e-05	9.25e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL2—prostate cancer	1.12e-05	9.22e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TERT—prostate cancer	1.12e-05	9.19e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CD—prostate cancer	1.12e-05	9.19e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ACHE—prostate cancer	1.12e-05	9.19e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTT1—prostate cancer	1.12e-05	9.19e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—APC—prostate cancer	1.12e-05	9.16e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CG—prostate cancer	1.12e-05	9.16e-05	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—PIK3CA—prostate cancer	1.11e-05	9.1e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SERPINE1—prostate cancer	1.11e-05	9.09e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2A6—prostate cancer	1.11e-05	9.08e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IRS1—prostate cancer	1.1e-05	9.06e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGF—prostate cancer	1.1e-05	9.06e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—KRAS—prostate cancer	1.1e-05	8.99e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—INS—prostate cancer	1.09e-05	8.96e-05	CbGpPWpGaD
Naltrexone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	1.09e-05	8.91e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKR1C3—prostate cancer	1.08e-05	8.83e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—FGF2—prostate cancer	1.07e-05	8.79e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—GSK3B—prostate cancer	1.07e-05	8.79e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—HIF1A—prostate cancer	1.07e-05	8.79e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PRKACB—prostate cancer	1.07e-05	8.79e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—CREBBP—prostate cancer	1.07e-05	8.78e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP17A1—prostate cancer	1.06e-05	8.69e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—NOS3—prostate cancer	1.06e-05	8.67e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—INS—prostate cancer	1.06e-05	8.67e-05	CbGpPWpGaD
Naltrexone—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.05e-05	8.6e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—LEP—prostate cancer	1.05e-05	8.58e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CAV1—prostate cancer	1.04e-05	8.5e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CREBBP—prostate cancer	1.04e-05	8.49e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—JAK2—prostate cancer	1.03e-05	8.43e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KDR—prostate cancer	1.02e-05	8.41e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IGF1—prostate cancer	1.02e-05	8.39e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—EGFR—prostate cancer	1.02e-05	8.35e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CD—prostate cancer	1.02e-05	8.33e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOA2—prostate cancer	1.01e-05	8.29e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—PIK3CA—prostate cancer	1.01e-05	8.26e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MDM2—prostate cancer	1e-05	8.23e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ESR1—prostate cancer	9.99e-06	8.19e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—ERBB2—prostate cancer	9.89e-06	8.11e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MAP2K1—prostate cancer	9.89e-06	8.11e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CD—prostate cancer	9.82e-06	8.05e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CB—prostate cancer	9.76e-06	8.01e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—BAD—prostate cancer	9.75e-06	8e-05	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—PIK3CA—prostate cancer	9.73e-06	7.98e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SERPINE1—prostate cancer	9.71e-06	7.97e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—SLC5A5—prostate cancer	9.64e-06	7.9e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—KRAS—prostate cancer	9.61e-06	7.89e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—NOS3—prostate cancer	9.58e-06	7.86e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CG—prostate cancer	9.44e-06	7.74e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—APC—prostate cancer	9.44e-06	7.74e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP2E1—prostate cancer	9.41e-06	7.72e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—FGF2—prostate cancer	9.4e-06	7.71e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CXCL8—prostate cancer	9.38e-06	7.69e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGF—prostate cancer	9.33e-06	7.65e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IRS1—prostate cancer	9.33e-06	7.65e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NQO1—prostate cancer	9.31e-06	7.63e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—NOS3—prostate cancer	9.27e-06	7.61e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TH—prostate cancer	9.17e-06	7.52e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1B—prostate cancer	9.16e-06	7.51e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP3A4—prostate cancer	9.08e-06	7.44e-05	CbGpPWpGaD
Naltrexone—OPRD1—GPCR downstream signaling—AKT1—prostate cancer	9.06e-06	7.43e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—GSK3B—prostate cancer	9.06e-06	7.43e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—JAK2—prostate cancer	9.01e-06	7.39e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CASP3—prostate cancer	8.98e-06	7.36e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL2—prostate cancer	8.96e-06	7.35e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—INS—prostate cancer	8.94e-06	7.33e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1B1—prostate cancer	8.92e-06	7.32e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—IL6—prostate cancer	8.92e-06	7.32e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CB—prostate cancer	8.85e-06	7.26e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—PIK3CA—prostate cancer	8.83e-06	7.24e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MDM2—prostate cancer	8.8e-06	7.22e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTGS2—prostate cancer	8.77e-06	7.19e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CREBBP—prostate cancer	8.75e-06	7.18e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CCND1—prostate cancer	8.74e-06	7.17e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—ERBB2—prostate cancer	8.67e-06	7.11e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CTNNB1—prostate cancer	8.65e-06	7.1e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IGF1—prostate cancer	8.64e-06	7.09e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GGT1—prostate cancer	8.64e-06	7.09e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—EGFR—prostate cancer	8.6e-06	7.05e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CB—prostate cancer	8.56e-06	7.02e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NCOA1—prostate cancer	8.51e-06	6.98e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MMP9—prostate cancer	8.48e-06	6.96e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—CDKN1A—prostate cancer	8.45e-06	6.93e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PTEN—prostate cancer	8.44e-06	6.92e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP19A1—prostate cancer	8.39e-06	6.88e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MAP2K1—prostate cancer	8.35e-06	6.85e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CD—prostate cancer	8.3e-06	6.81e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling by GPCR—AKT1—prostate cancer	8.23e-06	6.75e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CXCL8—prostate cancer	8.23e-06	6.75e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—PIK3CA—prostate cancer	8.22e-06	6.74e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SERPINE1—prostate cancer	8.21e-06	6.73e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—KRAS—prostate cancer	8.13e-06	6.66e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—RXRA—prostate cancer	8.1e-06	6.64e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EP300—prostate cancer	8.04e-06	6.6e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1B—prostate cancer	8.03e-06	6.59e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—FGF2—prostate cancer	7.95e-06	6.52e-05	CbGpPWpGaD
Naltrexone—OPRK1—GPCR downstream signaling—AKT1—prostate cancer	7.95e-06	6.52e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CASP3—prostate cancer	7.87e-06	6.46e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL2—prostate cancer	7.86e-06	6.45e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—NOS3—prostate cancer	7.84e-06	6.43e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—SRC—prostate cancer	7.82e-06	6.42e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—IL6—prostate cancer	7.82e-06	6.42e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—COMT—prostate cancer	7.8e-06	6.4e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTP1—prostate cancer	7.76e-06	6.37e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CCND1—prostate cancer	7.66e-06	6.29e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PTEN—prostate cancer	7.65e-06	6.27e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ITPR1—prostate cancer	7.64e-06	6.26e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—VEGFA—prostate cancer	7.62e-06	6.25e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—JAK2—prostate cancer	7.62e-06	6.25e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CTNNB1—prostate cancer	7.59e-06	6.22e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—STAT3—prostate cancer	7.54e-06	6.19e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—PIK3CA—prostate cancer	7.47e-06	6.12e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MMP9—prostate cancer	7.44e-06	6.1e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MDM2—prostate cancer	7.44e-06	6.1e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—CDKN1A—prostate cancer	7.41e-06	6.08e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PTEN—prostate cancer	7.4e-06	6.07e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—ERBB2—prostate cancer	7.33e-06	6.01e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—EP300—prostate cancer	7.29e-06	5.98e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CB—prostate cancer	7.23e-06	5.93e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—TYMS—prostate cancer	7.22e-06	5.92e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling by GPCR—AKT1—prostate cancer	7.22e-06	5.92e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—GSTM1—prostate cancer	7.13e-06	5.85e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EP300—prostate cancer	7.05e-06	5.79e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—MYC—prostate cancer	7.01e-06	5.75e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—LPL—prostate cancer	7e-06	5.74e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TGFB1—prostate cancer	6.99e-06	5.74e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CXCL8—prostate cancer	6.95e-06	5.7e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—SRC—prostate cancer	6.86e-06	5.63e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—EGFR—prostate cancer	6.86e-06	5.62e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1B—prostate cancer	6.79e-06	5.57e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CYP1A1—prostate cancer	6.76e-06	5.55e-05	CbGpPWpGaD
Naltrexone—OPRM1—GPCR downstream signaling—AKT1—prostate cancer	6.72e-06	5.51e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—ERCC2—prostate cancer	6.71e-06	5.5e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—VEGFA—prostate cancer	6.68e-06	5.48e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CASP3—prostate cancer	6.65e-06	5.46e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL2—prostate cancer	6.64e-06	5.45e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—STAT3—prostate cancer	6.62e-06	5.43e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—IL6—prostate cancer	6.61e-06	5.42e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—KRAS—prostate cancer	6.48e-06	5.31e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CCND1—prostate cancer	6.48e-06	5.31e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CTNNB1—prostate cancer	6.41e-06	5.26e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—MTHFR—prostate cancer	6.3e-06	5.17e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MMP9—prostate cancer	6.29e-06	5.16e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—CDKN1A—prostate cancer	6.27e-06	5.14e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PTEN—prostate cancer	6.25e-06	5.13e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PPARA—prostate cancer	6.18e-06	5.07e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—MYC—prostate cancer	6.15e-06	5.04e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TGFB1—prostate cancer	6.13e-06	5.03e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling by GPCR—AKT1—prostate cancer	6.1e-06	5e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—EGFR—prostate cancer	6.01e-06	4.93e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EP300—prostate cancer	5.96e-06	4.89e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—PIK3CA—prostate cancer	5.95e-06	4.88e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CAV1—prostate cancer	5.82e-06	4.77e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—SRC—prostate cancer	5.8e-06	4.75e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—TP53—prostate cancer	5.76e-06	4.72e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—KRAS—prostate cancer	5.68e-06	4.66e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—VEGFA—prostate cancer	5.65e-06	4.63e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—STAT3—prostate cancer	5.59e-06	4.59e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—PIK3CA—prostate cancer	5.39e-06	4.42e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CG—prostate cancer	5.3e-06	4.34e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—IL6—prostate cancer	5.27e-06	4.32e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—PIK3CA—prostate cancer	5.22e-06	4.28e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—MYC—prostate cancer	5.19e-06	4.26e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TGFB1—prostate cancer	5.18e-06	4.25e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—EGFR—prostate cancer	5.08e-06	4.17e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—TP53—prostate cancer	5.05e-06	4.14e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—INS—prostate cancer	5.01e-06	4.11e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—CREBBP—prostate cancer	4.91e-06	4.03e-05	CbGpPWpGaD
Naltrexone—OPRD1—Signaling Pathways—AKT1—prostate cancer	4.86e-06	3.99e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—KRAS—prostate cancer	4.8e-06	3.94e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CD—prostate cancer	4.66e-06	3.82e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—IL6—prostate cancer	4.62e-06	3.79e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—PIK3CA—prostate cancer	4.41e-06	3.62e-05	CbGpPWpGaD
Naltrexone—UGT1A1—Metabolism—AKT1—prostate cancer	4.41e-06	3.61e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—NOS3—prostate cancer	4.4e-06	3.61e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—TP53—prostate cancer	4.27e-06	3.5e-05	CbGpPWpGaD
Naltrexone—OPRK1—Signaling Pathways—AKT1—prostate cancer	4.26e-06	3.5e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CB—prostate cancer	4.06e-06	3.33e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTGS2—prostate cancer	4.02e-06	3.3e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—IL6—prostate cancer	3.91e-06	3.2e-05	CbGpPWpGaD
Naltrexone—OPRM1—Signaling Pathways—AKT1—prostate cancer	3.6e-06	2.95e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PTEN—prostate cancer	3.51e-06	2.88e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—EP300—prostate cancer	3.34e-06	2.74e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—PIK3CA—prostate cancer	2.47e-06	2.03e-05	CbGpPWpGaD
Naltrexone—ABCB1—Metabolism—AKT1—prostate cancer	2.02e-06	1.66e-05	CbGpPWpGaD
